Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Biotechnology

Healthcare
$2.03 +2.84%

+$0.11 today

Market cap
$171.45M
Beta
0.97
P/E (TTM)
-5.5
EPS (TTM)
-$0.70
52W Low $1.35High $4.60

Volume 1.12M

Average 1.37M

ELDN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Eledon Pharmaceuticals, Inc.NASDAQ: ELDN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$39.03M, compared with -$6.5M a year earlier. Trailing-twelve-month EBITDA was -$78.03M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -27.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$39.03M-277.7% QoQ
Last fiscal yearDec 2025
-$45.27M-27.9% YoY
LTMMar 2026
-$78.03M-325.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-500.8%+100.0%+600.8 pp
1 year-27.9%+100.0%+127.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(45.27M) USD
Year-over-year change
-27.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ELDN compares with its peers on the latest reported figures

  • ELDN's LTM Mar 2026 EBITDA of -$78.03M is the 4th highest of the 11 companies compared; the peer median is -$106.31M.
  • Its year-over-year change of -325.2% is the 10th highest of 11, against a peer median of -24.0%.
ELDN Competitors Peer median
EBITDA for ELDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABEOAbeona Therapeutics Inc.LTM Mar 2026$73.43M +298.8%—505.0%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$44.91M -17.8%+34.6%19.8%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$50.86M -14.6%——
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026-$78.03M -325.2%——
HUMAHumacyte, Inc.LTM Mar 2026-$79.77M -33.1%—3956.7%
EDITEditas Medicine, Inc.LTM Mar 2026-$100.08M +56.8%—258.7%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$112.54M -37.5%—308.4%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-$136.24M -213.5%—62.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$160.41M +32.7%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-$164.87M -697.5%—2873.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$179.89M -30.1%——
Peer median (excluding ELDN) -$106.31M-24.0%+34.6%308.4%

Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development23.74M27.08M30.31M51.96M66.27M
Selling, General & Admin13.13M12.7M12.69M18.61M16.98M
Operating Expenses36.87M88.43M43M70.58M83.25M
Depreciation & Amortization195K373K374K359K313K
EBITDA(36.67M)(39.41M)(116.16M)(35.39M)(45.27M)
EBITDA Margin—————
Operating Income(36.87M)(88.43M)(43M)(70.58M)(83.25M)
Operating Margin—————
Interest Income00000
Interest Expense00000
Other Income / Expenses7K462K(73.54M)34.82M37.67M
Income Before Tax(36.86M)(87.97M)(116.54M)(35.75M)(45.58M)
Pre-Tax Margin—————
Income Tax Expense(2.35M)00431K35K
Net Income(34.51M)(87.97M)(116.54M)(36.18M)(45.62M)
Net Margin—————
EPS (Basic)(2.33)(6.16)(4.73)(0.75)(0.56)
EPS (Diluted)(2.33)(6.16)(4.73)(0.75)(0.56)
Weighted Avg Shares14.82M14.29M24.62M48.54M81.84M
Weighted Avg Shares (Diluted)14.82M14.29M24.62M48.54M81.84M

Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Intrinsic Alpha fair value

Locked

Current Price

$2.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.